Proton (1H) MR spectroscopy of the breast.

Proton (hydrogen 1) [1H]) magnetic resonance (MR) spectroscopy provides biochemical information about the tissue under investigation. Its diagnostic value in cancer is typically based on the detection of elevated levels of choline compounds, choline being a marker of active tumor. The two main potential clinical applications of 1H MR spectroscopy are (a) as an adjunct to breast MR imaging to improve specificity in differentiating benign from malignant lesions, and (b) for monitoring or even predicting response to treatment in patients undergoing neoadjuvant chemotherapy. Preliminary data are promising, with study results suggesting that 1H MR spectroscopy may decrease the number of benign biopsies recommended on the basis of MR imaging findings and may help predict response as early as 24 hours after the first dose of neoadjuvant chemotherapy. Although several limitations currently exist that make the technique premature for clinical use, further evaluation with larger, preferably multicenter trials is certainly warranted.

[1]  Wei-Tse Yang,et al.  Breast cancer: in vivo proton MR spectroscopy in the characterization of histopathologic subtypes and preliminary observations in axillary node metastases. , 2002, Radiology.

[2]  Elizabeth A Morris,et al.  Nonpalpable mammographically occult invasive breast cancers detected by MRI. , 2006, AJR. American journal of roentgenology.

[3]  K. Offit,et al.  Breast MRI for women with hereditary cancer risk. , 2004, JAMA.

[4]  M D Schnall,et al.  MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. , 2001, Radiology.

[5]  An improved 1H magnetic resonance spectroscopic imaging technique for the human breast: preliminary results. , 2005, Magnetic resonance imaging.

[6]  K. Bae,et al.  Evaluation of 1H-Magnetic Resonance Spectroscopy of Breast Cancer Pre- and Postgadolinium Administration , 2005, Investigative radiology.

[7]  C Boetes,et al.  MR imaging in screening women at increased risk for breast cancer. , 2001, Magnetic resonance imaging clinics of North America.

[8]  L. Liberman,et al.  Breast cancer screening with MRI--what are the data for patients at high risk? , 2004, The New England journal of medicine.

[9]  I. Gribbestad,et al.  Characterization of neoplastic and normal human breast tissues with in vivo 1H MR spectroscopy , 1999, Journal of magnetic resonance imaging : JMRI.

[10]  I. Gribbestad,et al.  In vivo 1H MRS of normal breast and breast tumors using a dedicated double breast coil , 1998, Journal of magnetic resonance imaging : JMRI.

[11]  E. Morris.  Review of breast MRI: indications and limitations. , 2001, Seminars in roentgenology.

[12]  S. Singletary,et al.  Neoadjuvant chemotherapy in women with invasive breast carcinoma: conceptual basis and fundamental surgical issues. , 2000, Journal of the American College of Surgeons.

[13]  R. Lenkinski,et al.  Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. , 2002, Journal of the National Cancer Institute.

[14]  N. Hylton,et al.  Diagnostic architectural and dynamic features at breast MR imaging: multicenter study. , 2006, Radiology.

[15]  B. Tomanek,et al.  Specificity of choline metabolites for in vivo diagnosis of breast cancer using 1H MRS at 1.5 T , 2005, European Radiology.

[16]  Wei Huang,et al.  Detection of breast malignancy: diagnostic MR protocol for improved specificity. , 2004, Radiology.

[17]  R. Lenkinski,et al.  Human breast lesions: characterization with proton MR spectroscopy. , 1998, Radiology.

[18]  Elizabeth A Morris,et al.  MRI of occult breast carcinoma in a high-risk population. , 2003, AJR. American journal of roentgenology.

[19]  Winnie C W Chu,et al.  Characterization of lesions of the breast with proton MR spectroscopy: comparison of carcinomas, benign lesions, and phyllodes tumors. , 2003, AJR. American journal of roentgenology.

[20]  D. Bluemke,et al.  Proton magnetic resonance spectroscopic imaging of human breast cancer: A preliminary study , 2004, Journal of magnetic resonance imaging : JMRI.

[21]  K. Brandt,et al.  Adding in vivo quantitative 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of observer performance study at 4.0 T. , 2005, Radiology.

[22]  Wei Huang,et al.  Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study. , 2006, Radiology.

[23]  Robert E. Lenkinski,et al.  The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy , 2001, Breast Cancer Research and Treatment.

[24]  W. Negendank,et al.  Studies of human tumors by MRS: A review , 1992, NMR in biomedicine.

[25]  S. Dwivedi,et al.  Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer , 2001, British Journal of Cancer.

[26]  D. Yeung,et al.  Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy--initial results. , 2001, Radiology.

[27]  Michael Garwood,et al.  In vivo quantification of choline compounds in the breast with 1H MR spectroscopy , 2003, Magnetic resonance in medicine.

[28]  D. Yee,et al.  Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T. , 2004, Radiology.